OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.75
−0.04%Year over year
Reported trailing growth
- Revenue
- -2.5%
- EBITDA
- -13.4%
- EBIT
- -11.6%
- EPS
- -70.8%
- Free cash flow
- +3.3%
- Operating cash flow
- -10.8%
Forward estimates
Based on analyst estimates
- Revenue
- -1.7%
- EBITDA
- +45.8%
- EPS
- +341.8%
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -9.8%
- EBIT
- -9.0%
- Net income
- -41.1%
- EPS
- -41.6%
- Free cash flow
- +7.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026